National Academies Press: OpenBook

Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century (2016)

Chapter: Appendix A: Biographical Information of Committee and Staff

« Previous: 13 Operationalizing the New Regulatory Framework for the Federal Investment in Research Institutions
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

Appendix A

Biographical Information of Committee and Staff

Chair

LARRY R. FAULKNER is president emeritus of the University of Texas at Austin and is a retired president of Houston Endowment, a private philanthropy established by Jesse H. and Mary Gibbs Jones. Dr. Faulkner was born in Shreveport, Louisiana, in 1944. He earned a BS degree from Southern Methodist University in 1966 and a Ph.D. in chemistry from the University of Texas at Austin in 1969. Dr. Faulkner served on the chemistry faculties of Harvard University (1969–1973), the University of Illinois (1973–1983, 1984–1998), and the University of Texas (1983–1984, 1998–2006). At Illinois he was head of the Department of Chemistry, dean of the College of Liberal Arts and Sciences, and provost and vice chancellor for academic affairs. In 1998, he returned to the University of Texas at Austin as the 27th president, and served into 2006. Dr. Faulkner became president of Houston Endowment Inc. immediately thereafter and ultimately retired in 2012.

Dr. Faulkner has published more than 120 scientific papers and directed 40 doctoral theses. He also is coauthor (with Allen J. Bard) of the prominent text Electrochemical Methods: Fundamentals and Applications and is coinventor (with Peixin He and James Avery) of the cybernetic potentiostat, which had a lasting impact on the design of commercial analytical instruments. He has been recognized with the Electrochemical Society’s Edward Goodrich Acheson Medal, the American Chemical Society Award in Analytical Chemistry, the U.S. Department of Energy Award for Outstanding Scientific Achievement in Materials Chemistry, and the Charles N. Reilly Award of the Society for Electroanalytical Chemistry. In 2003, he was elected to the American Academy of Arts and Sciences.

As president of the University of Texas at Austin, he oversaw a capital campaign that raised over $1.6 billion. He also appointed and supported the work of the Commission of 125, a citizens’ group that provided guidance on the future of the university and its relationship to the public. Other significant achievements included the development of the Blanton Museum of Art, the acquisition of the

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

Suida-Manning Collection of European Art and the Woodward-Bernstein Watergate Archive, and the creation of innovative scholarship programs that helped to restore the University of Texas’s minority student enrollment. As president of Houston Endowment, he oversaw grant making of more than $400 million to charities in Greater Houston, focusing on arts and culture, education, the environment, health, and human services. From 2006 into 2008, he chaired the National Mathematics Advisory Panel by designation of the president and the secretary of education. From 2011 into 2013, he chaired the American Chemical Society’s Presidential Commission on Advancing Graduate Education in the Chemical Sciences. In 2014–2015, he was vice chair of the Texas Higher Education Coordinating Board’s Higher Education Strategic Planning Committee, which produced the state’s next 15-year plan, 60×30TX.

He now serves on the boards of Exxon Mobil Corporation, Southern Methodist University, Discovery Green Conservancy, Houston Grand Opera, the Philosophical Society of Texas, and Al Akhawayn University in Ifrane, Morocco. He was previously on the boards of Temple-Inland, Sandia National Laboratories, and the Lyndon Baines Johnson Foundation; and he chaired the Board of Trustees of Internet2 for a 3-year period ending in 2007.

Vice Chair

HARRIET RABB, JD, is vice president and general counsel to The Rockefeller University. Ms. Rabb was previously vice dean and faculty head of the clinical program, as well as a professor at Columbia Law School during her affiliation of more than two decades there. In 1991, she was named the first George M. Jaffin Professor of Law and Social Responsibility.

In 1993, Ms. Rabb was confirmed by the United States Senate to serve as general counsel for the U.S. Department of Health and Human Services under Secretary Donna Shalala. As chief legal officer of the department, Ms. Rabb was responsible for legal matters involving, among other agencies, the National Institutes of Health, the Centers for Disease Control, the Food and Drug Administration, the Health Care Financing Administration (now the Center for Medicare and Medicaid Services), and the Administration for Children and Families. Ms. Rabb led the department’s legal efforts on health policy issues, including human stem cell research, pandemic influenza, tobacco, assisted reproductive technology, tissue and organ allocation, fetal tissue and human embryo research, informed consent, and various aspects of vaccines. In 2001, Ms. Rabb was named to her current position as vice president and general counsel to The Rockefeller University.

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Members

ILESANMI ADESIDA (NAE) is dean emeritus of the College of Engineering and Donald Bigger Willett Professor of Engineering at the University of Illinois at Urbana-Champaign. He served as the vice chancellor for academic affairs and provost from 2012 to 2015. As the university’s chief academic officer, he oversaw the campus’s academic programs, policies, and priorities, which have been designed to ensure the quality of the educational experience for students and to sustain an environment that encourages and supports academic excellence. As the chief academic officer, Provost Adesida worked closely with the chancellor, the other vice chancellors, the deans of academic colleges and other units, academic staff, the Faculty Senate, and various committees in setting overall academic priorities for the campus.

In June 2005, Provost Adesida became the 13th dean since the inception of the College of Engineering in 1870. He originally joined the Illinois faculty in 1987, and he is currently the Donald Biggar Willett Professor of Engineering, professor of electrical and computer engineering, and professor of materials science and engineering. He has previously served as the director of the Micro and Nanotechnology Laboratory and the associate director for education of the National Science Foundation’s Engineering Research Center for Compound Semiconductor Microelectronics.

Provost Adesida’s research interests include nanofabrication processes and ultrahigh-speed optoelectronics. He has extensive experience in development of novel processes for wide bandgap materials such as silicon carbide and gallium nitride. He has also worked on ultra-high-speed photodetectors and photoreceivers in various materials systems. Provost Adesida has chaired many international conferences, including serving as the program and general chair of the Electronic Materials Conference, 2000–2003. He is a fellow of the Institute of Electrical and Electronic Engineers (IEEE), American Association for the Advancement of Science (AAAS), American Vacuum Society (AVS), and Optical Society of America. He won the 2016 TMS John Bardeen Award for excellence in electronic materials. He is past president of IEEE Electron Devices Society, and is a member of the National Academy of Engineering.

Provost Adesida received his B.S., M.S., and Ph.D. degrees in electrical engineering from the University of California, Berkeley. From 1979to 1984, he worked in various capacities at what is now known as the Cornell Nanofabrication Facility and the School of Electrical Engineering, Cornell University, Ithaca, New York. He was the head of the Electrical Engineering Department at Tafawa Balewa University, Bauchi, Nigeria, from 1985to 1987.

ANN M. ARVIN (NAM) is vice provost and dean of research at Stanford University and the Lucile Salter Packard Professor of Pediatrics (Infectious Diseas-

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

es) and professor of microbiology and immunology. Her responsibilities as vice provost include serving as the cognizant academic dean for Stanford’s 18 major university-wide interdisciplinary laboratories, centers, and institutes and overseeing university research policies, compliance with research regulations pertaining to human and animal research and laboratory safety, the Office of Technology Licensing/Industry Contracts Office, and shared facilities. Her research laboratory investigates the molecular mechanisms of human herpes virus infections, focusing on varicella-zoster virus, and T cell immune responses to viral vaccines and has had continuous National Institutes of Health funding since 1985. Her work has been recognized by election to the American Academy of Arts and Sciences, the Institute of Medicine of the National Academy of Sciences (NAS), the American Association for the Advancement of Science, and the Association of American Physicians. She has received the Distinguished Graduate Award from the University of Pennsylvania’s School of Medicine, the Walter Hewlett Award from Stanford University School of Medicine, the John F. Enders Award of the Infectious Diseases Society of America, and the E. Mead Johnson Award for Pediatric Research, among others. She was chief of the Pediatric Infectious Diseases Division at the Packard Children’s Hospital from 1984 to 2006. Her recent and current national service includes the National Academy of Sciences Board on Life Sciences, the President’s Council of Advisors on Science and Technology working group on H1N1 influenza, the Institute Director’s Advisory Council of the National Institute of Allergy and Infectious Diseases and the NAS/National Research Council Committee on Responsible Science and the Committee on Science, Technology, and Law. Dr. Arvin is a graduate of Brown University, with an AB in philosophy; Brandeis University, with an M.A. in philosophy; and the University of Pennsylvania School of Medicine, and completed postdoctoral fellowship training at the University of California, San Francisco, and Stanford University.

BARBARA E. BIERER, MD, a hematologist-oncologist, is a professor of medicine at Harvard Medical School and the Brigham and Women’s Hospital. Dr. Bierer cofounded and now leads the Multi-Regional Clinical Trials Center of the Brigham and Women’s Hospital and Harvard, a university-wide and collaborative effort to improve standards for the planning and conduct of international clinical trials, with a particular focus in the developing world. In addition, she is the director of the Regulatory Foundations, Ethics, and the Law Program at the Harvard Catalyst, and is a recipient of the Harvard Clinical and Translational Science Award. From 2003 to 2014, Dr. Bierer served as senior vice president of research at the Brigham and Women’s Hospital, where she was the institutional official for human subjects and animal research, for biosafety, and for research integrity. During her tenure in this role, Dr. Bierer initiated the Brigham Research Institute and the Brigham Innovation Hub (iHub), a focus for entrepreneurship and innovation in health care. She established and was the founding director of the Center for Faculty Development and Diversity.

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

Dr. Bierer, a graduate of Harvard Medical School, completed her internal medicine residency at the Massachusetts General Hospital and her hematology and medical oncology training at the Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. Earlier in her career, Dr. Bierer served as vice president of patient safety and director of the Center for Patient Safety at the Dana Farber Cancer Institute (2002–2003) and chief of the Laboratory of Lymphocyte Biology at the National Heart, Lung, and Blood Institute of the National Institutes of Health in Bethesda, Maryland (1997–2002). She has held positions as director of pediatric stem cell transplantation at Dana-Farber Cancer Institute and Children’s Hospital.

In addition to her current responsibilities, Dr. Bierer chairs the Board of Trustees of the Edward P. Evans Foundation, a foundation supporting biomedical research, and serves on the Boards of Directors of Public Responsibility in Medicine and Research (PRIM&R) and Management Sciences for Health (MSH). She is the immediate past chair of the Secretary’s Advisory Committee for Human Research Protections. She has authored or coauthored more than 180 publications.

JONATHAN D. BREUL is an adjunct professor in Georgetown University’s McCourt School of Public Policy. He also serves on the UNESCO’s Oversight Advisory Committee and has also chaired a number of congressionally requested studies of federal agencies for the National Academy of Public Administration. Previously, he was executive director of the IBM Center for the Business of Government and a partner in IBM Global Business Services. The IBM Center annually sponsored two dozen independent research reports by top minds in academe and the nonprofit sector, produced a weekly Business of Government Hour radio show, and published the biannual Business of Government magazine, which is distributed to all government executives.

Formerly senior advisor to the deputy director for management in the Office of Management and Budget (OMB), Mr. Breul served as OMB’s senior career executive with primary responsibility for government-wide general management policies. He also served for 8 years as the U.S. delegate and elected vice chair of the Paris-based Organization for Economic Cooperation and Development’s (OECD) Public Management Committee. Mr. Breul is an elected fellow of the National Academy Public Administration (NAPA) and leads the Government Performance Coalition.

CLAUDE R. CANIZARES (NAS) is the Bruno Rossi Professor of Physics at the Massachusetts Institute of Technology (MIT). At MIT since 1971, he has served as vice president (2013–2015), vice president for research and associate provost (2006–2013), associate provost (2001–2006), and director of the Center for Space Research (1990–2002). He oversaw the MIT Lincoln Laboratory from 2001 to 2014. Professor Canizares is a principal investigator on NASA’s Chan-

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

dra X-ray Observatory and associate director of its science center. He has also worked on several other space astronomy missions and is author or coauthor of more than 230 scientific papers.

Professor Canizares’s service outside MIT has included the Department of Commerce’s National Advisory Council on Innovation and Entrepreneurship and the Emerging Technology and Research Advisory Committee and the National Academies of Sciences, Engineering, and Medicine Committee on Science, Technology, and the Law. He served as chair of the Academies’ Space Studies Board and was a member of the NASA Advisory Council and the Air Force Scientific Advisory Board, among others. He is also a member of the L-3 Communications, Inc., Board of Directors. Professor Canizares is a member of the National Academy of Sciences and the International Academy of Astronautics and is a fellow of the American Academy of Arts and Sciences, the American Physical Society, and the American Association for the Advancement of Science. He has also received several awards including decoration for Meritorious Civilian Service to the United States Air Force, the Goddard Medal, and two NASA public service medals.

ARTURO CASADEVALL (NAM), MD, Ph.D., is chair of the W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health. Formerly, he was Leo and Julia Forchheimer Professor of Microbiology and Immunology; chair of the Department of Microbiology and Immunology; and professor in the Department of Medicine at the Albert Einstein College of Medicine. He received his B.A. from Queens College, City University of New York, and MS, MD, and Ph.D. degrees from New York University. His laboratory is interested in the fundamental questions of how microbes cause disease and how the host protects itself against microbes. The laboratory has a multidisciplinary research program spanning several areas of basic immunology and microbiology to address these general questions, which has resulted in more than 650 publications. His laboratory studies are focused on two microbes: the fungus Cryptococcus neoformans, a ubiquitous environmental microbe that is a frequent cause of disease in immunocompromised individuals, Bacillus anthracis, which is a major agent of biological warfare and Mycobacterium tuberculosis, the cause of tuberculosis. He is a fellow of the American Academy of Microbiology and was elected to the American Society for Clinical Investigation, to the American Association of Physicians, and as a fellow of the American Association for the Advancement of Science. Dr. Casadevall has served on numerous advisory committees to the National Institutes of Health, including study sections, strategic planning for the National Institute of Allergy and Infectious Diseases (NIAID), and the blue ribbon panel on response to bioterrorism. He currently cochairs the Board of Scientific Counselors for the NIAID and is a former member of the National Science Advisory Board for Biosecurity (NSABB). He is editor in chief of mBio, serves on the editorial boards of several journals, and has been the recipient of numerous

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

awards, most recently the Solomon A. Berson Medical Alumni Achievement Award in Basic Science of the NYU School of Medicine, the IDSA Kass Lecturer, and the William Hinton Award from the American Society of Microbiology for his efforts in mentoring scientists from underrepresented groups. He is a member of the National Academy of Medicine.

JONATHAN R. COLE, Ph.D., is the John Mitchell Mason Professor of the University, and for 14 years, from 1989 to 2003, he was provost and dean of faculties of Columbia University. He has spent his academic career at Columbia. From 1987 to 1989 he was vice president of arts and sciences. His early scholarly work focused principally on the development of the sociology of science as a research specialty. He published many books and articles on this subject. More recently, his published work addresses issues in higher education. His three most recent books on that subject are The Great American University: Its Rise to Preeminence, Its Indispensable National Role, Why It Must Be Preserved (2011), Who’s Afraid of Academic Freedom? (2015), and Toward a More Perfect University (2016). He lectures throughout the world on topics related to higher education. Dr. Cole was a fellow at the Center for Advanced Study in the Behavioral Sciences from 1975 to 1976. He was awarded a John Simon Guggenheim Foundation Fellowship (1975–1976). He spent the 1986–1987 academic year as a visiting scholar at the Russell Sage Foundation. In 1992 he was elected a fellow of the American Academy of Arts and Sciences. He is an elected member of the American Philosophical Society; elected member of the Council on Foreign Relations; and an elected fellow of the American Association for the Advancement of Science. He received his B.A. in American history from Columbia College in 1964 and his Ph.D. in sociology from Columbia in 1969. From 1968 until today, he has taught at Columbia. He was the Adolphe Quetelet Professor of Social Science, 1989 to 2001; professor of sociology, Columbia University, from 1976 until he became provost in 1989. He was adjunct professor at The Rockefeller University from 1983 to 1985.

LEE M. ELLIS, MD, is professor of surgical oncology, and molecular and cellular oncology and the William C. Liedtke, Jr. Chair in Cancer Research, at the University of Texas MD Anderson Cancer Center, and SWOG vice chair of translational medicine. Dr. Ellis graduated from the University of Virginia School of Medicine in 1983, and completed his residency in surgery at the University of Florida in 1990. Dr. Ellis went on to complete a surgical oncology fellowship at the MD Anderson Cancer Center (MDACC), where he has been on the faculty since 1993. Dr. Ellis has a clinical practice in surgical oncology, focused on patients with colorectal cancer and liver metastases. Academically, Dr. Ellis has established a reputation for expertise in the area of angiogenesis and growth factor receptors in gastrointestinal malignancies and is funded by several grants for research in this area. He has served on numerous National Institutes of Health (NIH) study sections and is a consultant to the National Cancer Institute (NCI), where he currently serves on the NCI Investigational Drug Steering

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

Committee (IDSC), and is vice chair of the NCI Colon Task Force. Dr. Ellis serves as an inaugural cochair of the NCI National Clinical Trials Network Correlative Sciences Committee. In 2000, Dr. Ellis was awarded the Faculty Scholar Award from the MDACC, and he was also the inaugural recipient of a grant from the George and Barbara Bush Endowment for Innovative Cancer Research. In 2007 he was awarded the William C. Liedtke, Jr., Chair in Cancer Research. Dr. Ellis serves on eight editorial boards, including serving as a deputy editor for JAMA Oncology.

Dr. Ellis has also authored more than 230 peer-reviewed publications, 110 invited reviews and editorials, 4 books, and 30 book chapters. Dr. Ellis served as interim chair of the Department of Cancer Biology from 2008 to 2012, and he also served as director of the Metastasis Research Center from 2010 to 2012 at the MDACC. Dr. Ellis served as codirector for the ASCO/AACR Workshop on Methods in Clinical Cancer Research from 2010 to 2012, and now serves as codirector of the FLIMS Workshop on Methods in Clinical Cancer Research. In May 2013 he assumed the position of vice chair for Translational Medicine of SWOG and serves on the Executive Committee for this organization. He is also on the Board of the Hope Foundation, the philanthropic arm of SWOG. Dr. Ellis is a member of the Nominating Committee of ASCO, a position he will hold until 2016. He chaired the ASCO Cancer Research Committee from 2012 to 2013.

Dr. Ellis’s interest in data reproducibility was highlighted by a comment in Nature in 2012, followed by a survey on data reproducibility from investigators at the MD Anderson Cancer Center. He participated in a replication workshop held in at NCI/NIH in September 2012 and has lectured on this topic at numerous international meetings.

GEOFFREY E. GRANT is president of Research Advocates. Mr. Grant has extensive management experience in public and academic institutions and has been recognized as an advocate for national research programs and the scientific community while promoting responsible stewardship of public funds. Mr. Grant worked 25 years at NIH, serving as director of the Office of Policy for Extramural Research Administration before he went to Stanford University as associate vice president for research administration. He returned to Washington, D.C., on a dual assignment at the National Science Foundation and the White House Office of Science and Technology Policy, where he worked with all federal research agencies to streamline and facilitate multidisciplinary and interdisciplinary research. Mr. Grant was later vice president for research administration of Partners HealthCare, one of the nation’s leading biomedical research organizations with approximately $1 billion of research support. He has received many honors and awards for research administration, including appointment to the Federal Senior Executive Service, the Society of Research Administrators Distinguished Contribution to Research Administration award, and the Association

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

of Independent Research Institutes (AIRI) Public Service Award. He now consults with universities on matters of grant opportunities, research policy, regulation, and compliance.

JOSEPH R. HAYWOOD, Ph.D., is Professor of Pharmacology and Toxicology and Assistant Vice President for Regulatory Affairs at Michigan State University (MSU). Dr. Haywood received his Ph.D. at the University of Florida and did post-doctoral work at the Cardiovascular Center at the University of Iowa. He rose through the ranks at the University of Texas Health Science Center at San Antonio before joining the Department of Pharmacology and Toxicology at MSU as professor and chair in 2002. In 2008 he became assistant vice president for regulatory affairs and remained as department chair until 2011. Dr. Haywood’s research interests have been in the area of neurohumoral control of arterial pressure, especially in experimental models of hypertension. He has focused on the action of circulating hormones and diet on neurotransmitter control in the hypothalamus in regulating the sympathetic nervous system.

Dr. Haywood is a former president of Federation of American Societies for Experimental Biology (FASEB). In 2012, he served as FASEB vice president for science policy and has also served as chair of FASEB’s Animals in Research and Education Subcommittee and Public Affairs Committee. Dr. Haywood is an active member of two FASEB societies. He is a member of the American Physiological Society and has served on its Council, and he is a member of the American Society for Pharmacology and Experimental Therapeutics. He has also been active in the leadership of the American Heart Association Council for High Blood Pressure Research. Dr. Haywood has served on the Council on Accreditation for the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and the Board of Governors of the International Council for Laboratory Animal Science (ICLAS). He co-chaired the committee that revised the CIOMS-ICLAS International Guiding Principles for the use of Animals in Research.

STEVEN JOFFE, MD, MPH, is the Emanuel and Robert Hart Associate Professor of Medical Ethics and Health Policy at the University of Pennsylvania Perelman School. He serves as vice chair of the department and directs the Fellowship in Advanced Biomedical Ethics. He is also associate professor of pediatrics at the Perelman School of Medicine. Dr. Joffe attended Harvard College, received his medical degree from the University of California, San Francisco (UCSF), and received his public health degree from the University of California, Berkeley. He trained in pediatrics at UCSF and undertook fellowship training in pediatric hematology/oncology at the Dana-Farber Cancer Institute and Boston Children’s Hospital. His clinical work is in the area of stem cell transplantation in children. His research addresses the many ethical challenges that arise in the conduct of clinical and translational investigation, both in pediatric oncology and other areas of medicine and science. He has led studies that examine the

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

roles and responsibilities of principal investigators in multicenter randomized trials, accountability in the clinical research enterprise, return of individual genetic results to participants in epidemiologic cohort studies, the integration of genomic sequencing technologies into the clinical care of cancer patients, and the governance of learning activities within learning health care systems. He currently serves as chair of the Children’s Oncology Group Bioethics Committee and as a member of the U.S. Food and Drug Administration’s (FDA) Pediatrics Ethics Subcommittee. In addition, he recently completed a term as a member of the Department of Health and Human Services Secretary’s Advisory Committee on Human Research Protections (SACHRP).

DAVID KORN (NAM), MD, Harvard University, is professor of pathology of Massachusetts General Hospital and Harvard Medical School. From November 15, 2008, to June 30, 2011, he was the inaugural vice provost for research at Harvard University. Prior to joining Harvard, Dr. Korn had served as the chief scientific officer of the Association of American Medical Colleges (AAMC) in Washington, D.C., since January 15, 2007, and before that as the senior vice president for biomedical and health sciences research at the association since September 1, 1997.

Dr. Korn served as Carl and Elizabeth Naumann Professor and Dean of the Stanford University School of Medicine from October 1984 to April 1995, and as vice president of Stanford University from January 1986 to April 1995. Previously, he had served as professor and founding chairman of the Department of Pathology at Stanford, and chief of the Pathology Service at the Stanford University Hospital, since June 1967. Dr. Korn has been chairman of the Stanford University Committee on Research; president of the American Association of Pathologists (now the American Society for Investigative Pathology), from which he received the Gold-Headed Cane Award for lifetime achievement in 2004; president of the Association of Pathology Chairs, from which he received the Distinguished Service Award in 1999; a member of the Board of Directors and of the Executive Committee of the Federation of American Societies for Experimental Biology; and a member of the Board of Directors of the Association of Academic Health Centers.

Dr. Korn served on the Board of Directors of the Stanford University Hospital from October 1982 to April 1995, the Children’s Hospital at Stanford from October 1984 to its closure, and the Lucile Salter Packard Children’s Hospital at Stanford from October 1984 to April 1995. He was a member of the Board of Directors of the California Society of Pathologists from 1983 to 1986. Dr. Korn has been a member of the editorial boards of the American Journal of Pathology, The Journal of Biological Chemistry, and Human Pathology, and for many years was an associate editor of the latter. He has sat on many society councils and boards. His nearly 200 publications range from bacteriophage biochemistry and genetics to the biochemistry and molecular biology of DNA replication in

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

human cells, and more recently, concern issues of academic values and integrity, research integrity, health and science policy, and financial conflicts of interest in academic medicine.

CHARLES F. LOUIS, Ph.D., is professor of neuroscience and cell biology emeritus at the University of California, Riverside, and former vice chancellor for research. Dr. Louis previously served as vice president for research at Georgia State University and served on the faculty at the University of Minnesota for more than 20 years, where he held a number of administrative positions that included head of the Department of Biochemistry, Molecular Biology and Biophysics from 1998 to 2000 and assistant vice president for research and associate dean of the Graduate School from 1994 to 1998. He previously held faculty appointments at the University of Connecticut Health Center and Leeds University in England.

Dr. Louis’s biomedical research on the role of calcium as an intracellular signaling molecule, which was funded by the National Institutes of Health for more than 25 years, used a range of different approaches, including cell physiology, molecular biology, biochemistry, cell biology, and biophysics. Dr. Louis is former chair of the Executive Committee of the Council of Research Policy and Graduate Education (CRPGE) of the Association of Public and Land-grant Universities (APLU), and a member of the Boards of Directors of APLU and the Council on Government Relations (COGR); he has served on many peer-review grant committees as well as the boards of biotech industry associations in both Minnesota and Georgia. Dr. Louis received his B.A. in chemistry from Trinity College, Dublin, Ireland, his Ph.D. in biochemistry from Oxford University, and postdoctoral training at Stanford University.

DAVID W. ROBINSON, Ph.D., is currently professor and executive vice provost at Oregon Health and Science University (OHSU) in Portland, Oregon. He obtained a BSc in physiology at University College London and a Ph.D. at Cambridge University. In 1992 he moved to the United States to do postdoctoral training at the University of California, Davis, where he subsequently became a research track faculty member before moving to OHSU in 1997.

Dr. Robinson’s research interests have been directed toward gaining a better understanding of the role retinal development plays in the maturation of the circadian and visual systems. Dr. Robinson also led the OHSU participation in the NCRR funded eagle-i Consortium, which was established to build a prototype of a national research resource discovery network to help biomedical scientists search for and find previously invisible, but highly valuable, research resources. He currently is the program director for the HRSA-funded Oregon Area Health Education Center at OHSU.

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

Dr. Robinson holds a faculty appointment as professor in the Department of Physiology and Pharmacology with joint appointments in the Department of Ophthalmology and the Oregon Institute of Occupational Health Science. At OHSU, Dr. Robinson’s administrative work began as the senior technology advisor for research and education in 2000. Subsequent to that, he served as vice provost for academic technology (2006), director of educational communications (2006), interim university librarian (2008), vice provost for academic technology and information services (2008), interim provost for education and research (2009), and interim provost and vice president for academic affairs (2010) before receiving his current appointment in 2011. Dr. Robinson has also been the OHSU faculty representative to the Federal Demonstration Partnership since 2002. In 2008, Dr. Robinson was elected for a 3-year term to the position of vice chair and, as a member of the Executive Committee, continues to work closely with senior staff members from the FDP’s Federal Agency partners, the Office of Science and Technology Policy, and the National Academies to improve the administrative processes involved with receiving funding from the federal government.

THOMAS J. ROSOL, DVM, Ph.D., is professor of veterinary biosciences at The Ohio State University. He served as the senior associate and interim senior vice president for research (2002–2005) and dean of the College of Veterinary Medicine (2005–2008) at The Ohio State University. Dr. Rosol currently serves as a senior advisor of life sciences for the university’s Office of Technology Commercialization and Knowledge Transfer.

Dr. Rosol served on advisory boards to the National Institutes of Health, Department of Agriculture, American Veterinary Medical Association, and Morris Animal Foundation. He is a consultant for industry in preclinical safety, toxicology, and animal models of cancer.

The Rosol laboratory investigates the pathogenesis of animal models of human cancer, mechanisms and treatment of bone metastasis, and endocrine-responsive cancers, and has been funded by the National Institutes of Health for 30 years. Recent work focuses on prostate, breast, head, and neck cancer, and lymphoma. Dr. Rosol has more than 280 publications and served as the mentor for 23 Ph.D. students and 20 postdoctoral trainees. The laboratory specializes in molecular investigations and mouse and dog in vivo studies using state-of-the-art imaging using bioluminescence, microCT, high-resolution ultrasound, MRI, and PET. Dr. Rosol is a fellow of the American Association for the Advancement of Science and was recognized by Ohio State University as a Distinguished Scholar, which is one of the universities’ highest honors. In 2015, Dr. Rosol was awarded the Annual Distinguished Mentor Award from the Society of Toxicologic Pathologists.

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

STUART SHAPIRO is an associate professor and director of the Public Policy Program at the Bloustein School of Planning and Policy at Rutgers University. He studies the process by which the federal government and the states issue regulations. His particular interest is the role that economics, science, and most importantly, politics play in regulatory decision making. In his 2016 book, Analysis and Public Policy: Successes, Failures, and Directions for Reform, he looked at the role that various types of analysis played in regulatory decisions. He found that politics, law, bureaucracy, and the limits of analysis itself placed bounds on the role of analysis but that, within these bounds, there was room for analytical influence on policy.

Dr. Shapiro also has a particular interest in cost-benefit analysis and teaches that subject to masters in public policy students. Before coming to Rutgers, he worked for the Office of Information and Regulatory Affairs in Washington, D.C., from 1998 to 2003, analyzing regulations from the Departments of Labor, Health and Human Services, Veterans Affairs, and numerous other agencies. He continues to be engaged in federal regulatory policy and has served as a consultant for the Administrative Conference of the United States.

STAFF

ANNE-MARIE MAZZA, Ph.D., is the senior director of the Committee on Science, Technology, and Law. Dr. Mazza joined the National Academies in 1995. She has served as senior program officer with both the Committee on Science, Engineering, and Public Policy and the Government-University-Industry Research Roundtable. In 1999 she was named the first director of the Committee on Science, Technology, and Law, a newly created activity designed to foster communication and analysis among scientists, engineers, and members of the legal community. Dr. Mazza has been the study director on numerous Academy activities and reports, including International Summit on Human Gene Editing: A Global Discussion (2016); Identifying the Culprit: Assessing Eyewitness Identification (2014); Positioning Synthetic Biology to Meet the Challenges of the 21st Century (2013); Reference Manual on Scientific Evidence, 3rd Edition (2011); Review of the Scientific Approaches Used During the FBI’s Investigation of the 2001 Anthrax Letters (2011); Managing University Intellectual Property in the Public Interest (2010); Strengthening Forensic Science in the United States: A Path Forward (2009); Science and Security in A Post 9/11 World (2007); Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health (2005); and Intentional Human Dosing Studies for EPA Regulatory Purposes: Scientific and Ethical Issues (2004). Between October 1999 and October 2000, Dr. Mazza divided her time between the National Academies and the White House Office of Science and Technology Policy, where she served as a senior policy analyst responsible for issues associated with a Presidential Review Directive on the government--

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

university research partnership. Before joining the Academy, Dr. Mazza was a senior consultant with Resource Planning Corporation. She is a fellow of the American Association for the Advancement of Science. Dr. Mazza was awarded a B.A., M.A., and Ph.D. from George Washington University.

THOMAS RUDIN is the director of the Board on Higher Education and Workforce at the National Academies—a position he assumed in mid-August 2014. Prior to joining the National Academies, Mr. Rudin served as senior vice president for career readiness and senior vice president for advocacy, government relations, and development at the College Board from 2006 to 2014. He was also vice president for government relations from 2004 to 2006 and executive director of grants planning and management from 1996 to 2004 at the College Board. Before joining the College Board, Mr. Rudin was a policy analyst at the National Institutes of Health in Bethesda, Maryland.

In 1991, Mr. Rudin taught courses in U.S. public policy, human rights, and organizational management as a visiting instructor at the Middle East Technical University in Ankara, Turkey. In the early 1980s, he directed the work of the Governor’s Task Force on Science and Technology for North Carolina Governor James B. Hunt, Jr., where he was involved in several new state initiatives, such as the North Carolina Biotechnology Center and the North Carolina School of Science and Mathematics. He received a bachelor of arts degree from Purdue University, and he holds master’s degrees in public administration and in social work from the University of North Carolina at Chapel Hill.

ELIZABETH O’HARE, Ph.D., was formerly a program officer with the Board on Higher Education and Workforce at the National Academies of Sciences, Engineering, and Medicine. Her portfolio included projects that addressed STEM workforce development, the higher education regulatory environment, and the competitiveness of American research universities. Dr. O’Hare left the National Academies in January 2016 to join Lewis-Burke Associates, a government relations firm specializing in advocating for the policy interests of higher education institutions and other research and education organizations. Prior to joining the National Academies, Dr. O’Hare served as a legislative assistant for Representative Rush Holt (NJ-12), where she handled energy, science, and education policy issues and staffed Rep. Holt in his role as the Senior Democrat on the Energy and Mineral Resources Subcommittee, House Committee on Natural Resources. Dr. O’Hare got her start in science policy after being selected by the Society for Research in Child Development as a 2010 American Association for the Advancement of Science (AAAS) Congressional Science Policy Fellow. She holds a Ph.D. in neuroscience from the University of California, Los Angeles, and an AB in psychology from Bryn Mawr College.

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

STEVEN KENDALL, Ph.D., is program officer for the Committee on Science, Technology, and Law. Dr. Kendall has contributed to numerous Academy reports, including International Summit on Human Gene Editing: A Global Discussion (2016); Identifying the Culprit: Assessing Eyewitness Identification (2014); Positioning Synthetic Biology to Meet the Challenges of the 21st Century (2013); the Reference Manual on Scientific Evidence, 3rd Edition (2011); Review of the Scientific Approaches Used During the FBI’s Investigation of the 2001 Anthrax Mailings (2011); Managing University Intellectual Property in the Public Interest (2010); and Strengthening Forensic Science in the United States: A Path Forward (2009). Dr. Kendall completed his Ph.D. in the Department of the History of Art and Architecture at the University of California, Santa Barbara, where he wrote a dissertation on 19th century British painting. Dr. Kendall received his M.A. in Victorian art and architecture at the University of London. Prior to joining the National Research Council in 2007, he worked at the Smithsonian American Art Museum and The Huntington in San Marino, California.

NINA BOSTON is a research associate in the Policy and Global Affairs (PGA) Division at the National Academies of Sciences, Engineering, and Medicine. Ms. Boston supports the InterAcademy Partnership and the Development, Security, and Cooperation unit. She formerly supported the Board on Higher Education and Workforce. She has a B.A. in anthropology from Elon University and is currently pursuing an MPP from the University of Maryland School of Public Policy.

KAROLINA KONARZEWSKA is program coordinator for the Committee on Science, Technology, and Law. She is a master’s student of economics at George Mason University. She holds a master’s degree in international relations from New York University and a bachelor’s degree in political science from the College of Staten Island, City University of New York. Prior to joining the National Academies, she worked at various research institutions in Washington, D.C., where she covered political and economic issues pertaining to Europe, Russia, and Eurasia.

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×

This page intentionally left blank.

Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 203
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 204
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 205
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 206
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 207
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 208
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 209
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 210
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 211
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 212
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 213
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 214
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 215
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 216
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 217
Suggested Citation:"Appendix A: Biographical Information of Committee and Staff." National Academies of Sciences, Engineering, and Medicine. 2016. Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century. Washington, DC: The National Academies Press. doi: 10.17226/21824.
×
Page 218
Next: Appendix B: Recommendations Table »
Optimizing the Nation's Investment in Academic Research: A New Regulatory Framework for the 21st Century Get This Book
×
Buy Paperback | $65.00 Buy Ebook | $54.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Research universities are critical contributors to our national research enterprise. They are the principal source of a world-class labor force and fundamental discoveries that enhance our lives and the lives of others around the world. These institutions help to create an educated citizenry capable of making informed and crucial choices as participants in a democratic society. However many are concerned that the unintended cumulative effect of federal regulations undercuts the productivity of the research enterprise and diminishes the return on the federal investment in research.

Optimizing the Nation's Investment in Academic Research reviews the regulatory framework as it currently exists, considers specific regulations that have placed undue and often unanticipated burdens on the research enterprise, and reassesses the process by which these regulations are created, reviewed, and retired. This review is critical to strengthen the partnership between the federal government and research institutions, to maximize the creation of new knowledge and products, to provide for the effective training and education of the next generation of scholars and workers, and to optimize the return on the federal investment in research for the benefit of the American people.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!